Nektar Therapeutics (FRA:ITH) ROCE % : -36.34% (As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nektar Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -36.34%.

Nektar Therapeutics ROCE % Historical Data

The historical data trend for Nektar Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics ROCE % Chart

Nektar Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-21.61

-25.42

-40.44

-41.75

-49.78

Nektar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-90.81	-37.85	-38.68	-37.82	-36.34

Nektar Therapeutics ROCE % Calculation

Nektar Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-230.095	/	( ( (670.806 - 64.385)	+	(364.996 - 47.014) )	/ 2 )
	=	-230.095	/	( (606.421	+	317.982)	/ 2 )
	=	-230.095	/	462.2015
	=	-49.78 %

Nektar Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-115.208	/	( ( (364.996 - 47.014)	+	(364.331 - 48.214) )	/ 2 )
	=	-115.208	/	( ( 317.982	+	316.117 )	/ 2 )
	=	-115.208	/	317.0495
	=	-36.34 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Nektar Therapeutics (FRA:ITH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nektar Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics (FRA:ITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (FRA:ITH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NKTR:USA

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Nektar Therapeutics (FRA:ITH) Headlines

No Headlines